In this episode, we explore triploidy, a rare and typically lethal chromosomal abnormality where a fetus possesses 69 chromosomes instead of the standard 46. We examine the two distinct phenotypes based on parental origin: diandric triploidy, often associated with a large, cystic placenta, and digynic triploidy, characterized by a small placenta and severe fetal growth restriction. The discussion highlights the limitations of non-invasive prenatal testing (NIPT) in detecting this condition due to low fetal DNA fractions, emphasizing the reliance on ultrasound and invasive testing for diagnosis. Finally, we address the complex management decisions parents face, ranging from termination to perinatal palliative care and the support resources available to them.

In this episode, we explore the complex landscape of Mucolipidosis types II and III (ML II/III), rare metabolic disorders caused by a breakdown in the cell's enzyme targeting system due to defects in the GNPTAB or GNPTG genes. We discuss the distinct 'I-cell' phenomenon where a deficiency in GlcNAc-1-phosphotransferase prevents lysosomal enzymes from acquiring the essential mannose 6-phosphate (M6P) tag, causing them to be lost in the bloodstream rather than reaching the lysosome to degrade cellular waste.

The episode compares the severe, life-limiting phenotype of ML II (formerly I-cell disease)—marked by early skeletal dysplasia (dysostosis multiplex), gingival hyperplasia, and rapid cardiorespiratory decline—with the attenuated ML III alpha/beta and gamma forms, where patients manage progressive joint stiffness, severe osteoporosis, and heart valve disease well into adulthood. Finally, we examine the shifting therapeutic horizon, highlighting M6P Therapeutics' investigational S1S3 gene therapy platform designed to restore enzyme phosphorylation and collaborative research into naturally occurring feline models aimed at modifying disease progression.

In this episode, we explore Gastrointestinal Stromal Tumours (GISTs), rare mesenchymal neoplasms originating from the interstitial cells of Cajal. We break down the critical role of immunohistochemistry—specifically CD117 and DOG1 markers—in accurate diagnosis, and how prognosis is strictly stratifed by tumour size, mitotic rate, and anatomical location. Finally, we examine the standard of care involving surgical resection and targeted Tyrosine Kinase Inhibitors (TKIs) like imatinib, alongside emerging therapies for rare, drug-resistant subtypes such as SDH-deficient and Quadruple Wild-Type GISTs.

In this episode, we examine the rising incidence and management of pleural empyema, a severe pulmonary condition characterized by pus in the pleural cavity. We discuss the utility of thoracic ultrasound and 16S rRNA sequencing for accurate diagnosis, and evaluate the latest evidence comparing intrapleural enzyme therapy (tPA/DNase) against surgical interventions like VATS, highlighting key findings from the MIST-3 feasibility trial.

In this episode, we explore Bronchopulmonary Dysplasia (BPD), the most common chronic respiratory disease in preterm infants characterized by arrested lung development and alveolar simplification. We examine the evolution of diagnostic criteria, highlighting how the 2019 Jensen definition offers superior predictive value for long-term neurodevelopmental outcomes compared to older consensus models. The discussion covers critical management strategies, including the protective effects of early caffeine therapy, the necessity of high-calorie nutrition to support lung repair, and standardized screening for BPD-associated pulmonary hypertension. Finally, we look at the future of care, ranging from the potential of mesenchymal stromal cell therapy to the lifelong respiratory risks, such as COPD-like phenotypes, faced by BPD survivors.

In this episode, we explore Stargardt disease (STGD1), the most prevalent form of inherited juvenile macular degeneration caused primarily by biallelic mutations in the ABCA4 gene, leading to the accumulation of toxic lipofuscin in the retina. We examine the significant "diagnostic odyssey" patients endure, often facing years of misdiagnosis and social stigma due to the invisible nature of their central vision loss.

Key highlights include the therapeutic inflection point of 2025, featuring the promising TEASE-2 trial results for oral gildeuretinol (ALK-001), which demonstrated a 28% reduction in retinal atrophy progression, and the advancement of Phase 3 trials for tinlarebant, an oral RBP4 antagonist designed to lower toxic vitamin A byproducts. We also discuss cutting-edge genetic interventions overcoming the large size of the ABCA4 gene, such as SpliceBio’s dual-vector protein splicing therapy and Ascidian’s RNA exon-editing technology. Finally, we review the critical need for diverse genetic screening, noting unique mutational landscapes in African American and Chinese populations that drive distinct clinical phenotypes.

In this episode, we explore the complex spectrum of conditions associated with the ELN gene and chromosome 7q11.23, contrasting 7q11.23 duplication syndrome—characterised by speech delays, anxiety, and aortic dilatation—with Williams syndrome, which results from a deletion in the same region. We examine the critical vascular manifestation of supravalvular aortic stenosis (SVAS), highlighting the severe risks associated with anaesthesia due to coronary perfusion compromise and comparing surgical strategies like the single-patch (McGoon) versus the two-patch (Doty) repair, with recent data favouring the latter for lower reintervention rates. Finally, we discuss ** ELN -related cutis laxa**, a rare disorder of skin inelasticity and emphysema caused by a dominant-negative mechanism rather than the elastin haploinsufficiency seen in SVAS.

In this episode, we explore Holoprosencephaly (HPE), a complex congenital malformation where the embryonic forebrain fails to divide into distinct hemispheres. We examine the wide clinical spectrum, ranging from the severe alobar form, often associated with major craniofacial anomalies like cyclopia, to milder microforms that may present with subtle features such as a single central incisor. The discussion covers the diverse etiology of the disorder, including chromosomal abnormalities, specific gene mutations in SHH and ZIC2, and environmental risk factors like maternal diabetes. Finally, we highlight the importance of multidisciplinary management for complications such as seizures and pituitary dysfunction, and review emerging data on long-term survival and developmental progress in affected children.

In this episode, we explore cystinuria, a rare genetic disorder caused by mutations in the SLC3A1 or SLC7A9 genes that impair renal reabsorption of cystine, leading to recurrent, debilitating kidney stones. We discuss the standard 'triple pillar' management of hyperhydration, urinary alkalinisation, and cystine-binding thiol drugs like tiopronin, while highlighting the significant burden of chronic kidney disease and hypertension facing these patients. Finally, we examine the promising therapeutic pipeline for 2025, including ADV7103 (a prolonged-release alkaliniser recently granted FDA Orphan Drug Designation), alpha-lipoic acid for crystal inhibition, and the potential repurposing of bucillamine and SGLT2 inhibitors.

In this episode, we examine Idiopathic Intracranial Hypertension (IIH), a condition characterized by elevated pressure within the skull that predominantly affects overweight women of childbearing age. We discuss the critical risk of permanent vision loss caused by papilledema (optic nerve swelling) and debilitating symptoms like chronic headaches and pulsatile tinnitus. Listeners will learn about the Modified Dandy Criteria used for diagnosis—which requires ruling out secondary causes via neuroimaging and confirming high pressure via lumbar puncture—and explore treatment landscapes ranging from weight loss and acetazolamide to surgical interventions like venous sinus stenting and emerging therapies using GLP-1 receptor agonists.